Virus-like particles: innate immune stimulators

References

• Bayer ME, Blumberg BS, Werner B. Particles associated with Australia antigen in the sera of patients with leukaemia, Down’s Syndrome and hepatitis. Nature218(5146), 1057–1059 (1968).
   PubMed Web of Science ®Google Scholar
• French TJ, Marshall JJ, Roy P. Assembly of double-shelled, viruslike particles of bluetongue virus by the simultaneous expression of four structural proteins. J. Virol.64(12), 5695–5700 (1990).
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology185(1), 251–257 (1991).
   PubMed Web of Science ®Google Scholar
• Yamshchikov GV, Ritter GD, Vey M, Compans RW. Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology214(1), 50–58 (1995).
   PubMed Web of Science ®Google Scholar
• Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods40(1), 60–65 (2006).
   PubMed Web of Science ®Google Scholar
• Meyer G, Deplanche M, Schelcher F. Human and bovine respiratory syncytial virus vaccine research and development. Comp. Immunol. Microbiol. Infect. Dis.31(2–3), 191–225 (2008).
   PubMedGoogle Scholar
• Openshaw PJ, Culley FJ, Olszewska W. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine20(Suppl. 1), S27–S31 (2001).
   PubMed Web of Science ®Google Scholar
• Moron G, Rueda P, Casal I, Leclerc C. CD8α- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8α and CD205 molecules. J. Exp. Med.195(10), 1233–1245 (2002).
   PubMed Web of Science ®Google Scholar
• Kurt-Jones EA, Popova L, Kwinn L et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol.1(5), 398–401 (2000).
   PubMed Web of Science ®Google Scholar
• Wilkins C, Gale M Jr. Recognition of viruses by cytoplasmic sensors. Curr. Opin. Immunol.22(1), 41–47 (2010).
   PubMed Web of Science ®Google Scholar
• Song H, Wittman V, Byers A et al. In vitro stimulation of human influenza-specific CD8+ T cells by dendritic cells pulsed with an influenza virus-like particle (VLP) vaccine. Vaccine28(34), 5524–5532 (2010).
   PubMedGoogle Scholar
• Gamvrellis A, Leong D, Hanley JC, Xiang SD, Mottram P, Plebanski M. Vaccines that facilitate antigen entry into dendritic cells. Immunol. Cell. Biol.82(5), 506–516 (2004).
   PubMed Web of Science ®Google Scholar
• Antonis AF, Bruschke CJ, Rueda P et al. A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure. Vaccine24(26), 5481–5490 (2006).
   PubMedGoogle Scholar
• Young SL, Wilson M, Wilson S, Beagley KW, Ward V, Baird MA. Transcutaneous vaccination with virus-like particles. Vaccine24(26), 5406–5412 (2006).
   PubMedGoogle Scholar
• Dell K, Koesters R, Linnebacher M, Klein C, Gissmann L. Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. Vaccine24(13), 2238–2247 (2006).
   PubMedGoogle Scholar
• Bright RA, Carter DM, Daniluk S et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine25(19), 3871–3878 (2007).
   PubMed Web of Science ®Google Scholar
• Sailaja G, Skountzou I, Quan FS, Compans RW, Kang SM. Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology362(2), 331–341 (2007).
   PubMed Web of Science ®Google Scholar
• Raghunandan RR, Massare ZBM, Smith G, Connolly K. Safety and efficacy of a novel RSV F-particle vaccine candidate in two preclinical RSV challenge models. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Boston, MA, USA, 12–15 September 2010.
   Google Scholar
• Mahmood K, Bright RA, Mytle N et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine26(42), 5393–5399 (2008).
   PubMed Web of Science ®Google Scholar
• Pushko P, Tumpey TM, Van Hoeven N et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine25(21), 4283–4290 (2007).
   PubMed Web of Science ®Google Scholar
• Quan FS, Huang C, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol.81(7), 3514–3524 (2007).
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Crevar CJ et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE3(1), e1501 (2008).
   PubMed Web of Science ®Google Scholar
• Heaton P. Virus like particle vaccine against pandemic intrapandemic (seasonal influenza viruses). Presented at: World Vaccine Conference. Lyon, France, 8 October 2008.
   Google Scholar
• Glenn G. Rapid responses during the 2009 (H1N1) pandemic in Mexico with a VLP vaccine. Presented at: 7th World Health Organization Meeting on Evaluation Of Pandemic Influenza Vaccines Trials. Geneva, Switzerland, 9–11 February 2011.
   Google Scholar
• Skountzou I, Quan FS, Gangadhara S et al. Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles. J. Virol.81(3), 1083–1094 (2007).
   PubMed Web of Science ®Google Scholar